A long-acting glucose-dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon-like peptide-1 receptor agonist therapy

Diabetes Obes Metab. 2024 Nov;26(11):5474-5478. doi: 10.1111/dom.15875. Epub 2024 Aug 27.
No abstract available

Keywords: GIP; GLP‐1; antidiabetic drug; antiobesity drug; clinical trial; incretin therapy.

Publication types

  • Letter

MeSH terms

  • Diabetes Mellitus, Type 2* / drug therapy
  • Female
  • Gastric Inhibitory Polypeptide / agonists
  • Gastric Inhibitory Polypeptide / therapeutic use
  • Glucagon-Like Peptide-1 Receptor Agonists*
  • Humans
  • Hypoglycemic Agents* / adverse effects
  • Hypoglycemic Agents* / therapeutic use
  • Male
  • Middle Aged
  • Receptors, Gastrointestinal Hormone / agonists

Substances

  • Hypoglycemic Agents
  • Receptors, Gastrointestinal Hormone
  • gastric inhibitory polypeptide receptor
  • Gastric Inhibitory Polypeptide
  • Glucagon-Like Peptide-1 Receptor Agonists

Grants and funding